20cm速递丨科创创新药ETF（589720）收涨超5%，去年“924行情”以来跑赢主要港股创新药指数，机构称医药板块利好不断

Group 1 - The pharmaceutical sector is experiencing positive developments, with a joint initiative from the National Health Commission and other departments aiming to enhance ear and hearing health services by 2030, targeting a coverage of over 90% in prefecture-level cities [1] - The medical device industry is expected to benefit from policy support, particularly in AI and imaging/surgical applications, with significant potential for domestic equipment replacement [1] - The impact of centralized procurement on the medical consumables sector is gradually diminishing, leading to a potential recovery in high-value consumables [1] Group 2 - The innovative drug sector is showing positive performance driven by policy and funding, with expectations for overseas business development and clinical data to catalyze industry upgrades [1] - The Chinese herbal medicine sector is nearing the end of inventory clearance, with attention on beneficiaries of innovation-driven and centralized procurement policies [1] - The CXO sector is seeing improvements in fundamentals, with orders increasing quarterly as the industry enters an upward cycle [1] Group 3 - China's innovative drugs are entering a phase of realization of results, with numerous research and development advancements that are not affected by trade frictions, expected to remain a key investment theme in the pharmaceutical sector through 2025 [1] - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies in the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies, primarily in high-growth biotech, with a 20% limit on daily price fluctuations to better align with sector volatility [1][2] Group 4 - Since the "924 market" rally last year, the Sci-Tech Innovation Drug Index has outperformed major Hong Kong innovation drug indices, with respective gains of 75%, 70%, and 70% during the market rebound from September 24, 2024, to June 30, 2025 [2] - The Sci-Tech Innovation Drug Index may help capture better returns when market risk appetite increases [2]